Jerome D. Jabbour

Insider Reports History

Reporting-owner location: Bedminster, NJ
Latest reporting-owner signature: /s/ Jerome Jabbour
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Jerome D. Jabbour

Form 4 holding President and CEO, Director

Matinas BioPharma Holdings, Inc.

Security class: Stock Option (right to Buy)
Shares / value: 70,100
Estimated value
Report date: 30 Apr 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Indaptus Therapeutics, Inc.

Security class: Option to Buy Common Stock
Shares / value: 25,000
Estimated value
Report date: 26 Feb 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Jerome D. Jabbour

4 INDP

Indaptus Therapeutics, Inc.

Report period: 26 Feb 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 27 Feb 2026, 16:06
Role: Director
Next action: Open filing details

3 INDP

Indaptus Therapeutics, Inc.

Report period: 26 Feb 2026
Transactions: 0
Transaction value: $0
Accepted by SEC: 27 Feb 2026, 16:05
Role: Director
Next action: Open filing details

4 MTNB

Matinas BioPharma Holdings, Inc.

Report period: 30 Apr 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 02 May 2025, 17:19
Role: President and CEO, Director
Next action: Open filing details

4 MTNB

Matinas BioPharma Holdings, Inc.

Report period: 15 Dec 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 Dec 2023, 21:46
Role: President and CEO, Director
Next action: Open filing details

4 MTNB

Matinas BioPharma Holdings, Inc.

Report period: 20 Dec 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 Dec 2022, 10:20
Role: President and CEO, Director
Next action: Open filing details

4 MTNB

Matinas BioPharma Holdings, Inc.

Report period: 14 Dec 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 Dec 2021, 20:29
Role: President and CEO, Director
Next action: Open filing details

4 MTNB

Matinas BioPharma Holdings, Inc.

Report period: 19 Jun 2021
Transactions: 3
Transaction value: $0
Accepted by SEC: 24 Jun 2021, 17:49
Role: President and CEO, Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .